Clinical trials: Hepatocellular Cancer
Hepatocellular Carcinoma
Predictors of Sorafenib Response in HCC
Evaluating the nutrition status of patients with advanced HCC who received sorafenib. Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
- Trial name
- NCT05967429
- Testing
- The neutrophil-to- lymphocyte ratio, Prognostic nutrition index
- Volunteers
- 80 people
- Sponsor
- Sohag University
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single…
- Conditions
- Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer
- Trial name
- ICEMELT (NCT04631731)
- Testing
- Blood screening, Tissue screening
- Where
- 2 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Western Sydney Local Health District
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC.
- Trial name
- NCT02234986
- Testing
- ENMD-2076
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- CASI pharmaceuticals, Inc.
Fibrolamellar Hepatocellular Carcinoma (FLC)
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC…
- Trial name
- NCT04248569
- Testing
- DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HepatoCellular Carcinoma
CHARM Hepatocellular Carcinoma MEA Study
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death worldwide.
- Trial name
- NCT07650773
- Where
- 17 sites in Egypt, Kuwait and 5 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Liver Transplant, Liver Cancer, Immunosuppressant
Analysis of Clinical Outcomes and Complications in Patients Received Liver Transplantation: A Retrospective Study
Liver transplantation is the last-line method for liver failure. Thomas Starzl completed the first liver transplant in 1967, liver transplantation is developing rapidly.
- Trial name
- NCT05587556
- Where
- Taiwan
- Volunteers
- 1,400 people
- Sponsor
- China Medical University Hospital
Hepatocellular Carcinoma Non-resectable, Chemoembolization, Therapeutic
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.
- Trial name
- SERENADE-T (NCT03283956)
- Testing
- Patient records
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Hepatic Small Vessel Neoplasm
Hepatic Small Vessel Neoplasm
Small-vessel hepatic tumor is a new tumor entity of vascular origin, described in 2016 by Gill et al, in a series of 17 patients.
- Trial name
- IMAHEP (NCT06067035)
- Testing
- Imaging
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of death from cancer worldwide1 . Hepatectomy is still the main effective treatment for HCC accompanying with well-preserved cirrhosis when liver…
- Trial name
- NCT02535117
- Testing
- Laparoscopic Surgery(LS), RFA
- Volunteers
- 216 people
- Sponsor
- Sun Yat-sen University
Rupture, Spontaneous
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular
Develop a new scoring system for HCC patients with tumor rupture.
- Trial name
- NCT03504358
- Testing
- Liver resection
- Volunteers
- 129 people
- Sponsor
- Huazhong University of Science and Technology
Liver Neoplasm, HBV Infection
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma…
- Conditions
- Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis
- Trial name
- NCT07265544
- Testing
- Collection of Preoperative Peripheral Blood, Collection of Discarded Liver Tissue During Surgery
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
Liver Tumors
Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study
The search for communicating veins (CVs) between adjacent hepatic veins (HVs) has drawn its rationale from living donor liver transplantation (LDLT).
- Trial name
- NCT00960609
- Testing
- Ultrasound guided liver resection
- Where
- Italy
- Sponsor
- University of Milan